-
Nov 10, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Eric Simpson
You've successfully added Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: More patients treated with roflumilast vs. vehicle achieved a validated IGA-AD score of 0/1. More than 95% of roflumilast-treated patients reported no signs of application site irritation.
-
Oct 4, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Eric Simpson
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Orismilast 40 mg group achieved the best results with 31% of patients reaching IGA 0 or 1 by week 16. IGA 0 or 1 was also achieved by 26% and 30 mg of the orismilast 20 mg and 30 mg groups, respectively.
-
Sep 18, 2024 | 
jamanetwork.com | Eric Simpson |Lawrence F. Eichenfield |Javier Alonso-Llamazares
Key PointsQuestion What is the efficacy and safety of once-daily roflumilast cream, 0.15%, in patients with atopic dermatitis (AD)? Findings In 2 phase 3 randomized clinical trials of 1337 individuals with AD, significantly more patients treated with once-daily roflumilast cream, 0.15%, achieved Validated Investigator Global Assessment for Atopic Dermatitis success at 4 weeks than patients treated with vehicle cream. Roflumilast was well tolerated with low rates of adverse events in both trials.
-
Mar 27, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Eric Simpson
Read more You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Ruxolitinib-treated patients achieved greater differences from baseline in itch intensity vs. vehicle.
-
Feb 14, 2024 | 
jamanetwork.com | Andrew Blauvelt |Henrique D Teixeira |Eric Simpson |Antonio Costanzo
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, MD, MBA; Henrique D. Teixeira, PhD, MBA; Eric L. Simpson, MD, MCR; Antonio Costanzo, MD; Marjolein De Bruin-Weller, MD; Sebastien Barbarot, MD, PhD; Vimal H.
-
Oct 13, 2023 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Eric Simpson
You've successfully added Dermatology: Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: As early as day 1, Vtama-treated patients saw an up to 1.6-point reduction in pruritus. By week 8, pruritus scores had decreased by 4.1 points in Vtama groups vs.
-
Oct 12, 2023 | 
dermatologytimes.com | Kaitlyn Bader |Eric Simpson
Dermavant Sciences announced today new pruritus data for tapinarof (VTAMA) cream 1% from its phase 3 trials, ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859), in adults and children down to 2 years of age with moderate to severe atopic dermatitis at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin, Germany.1 New data tapinarof cream data regarding pruritus relief includes: Greater reductions in Peak Pruritus-Numeric Rating Scale (PP-NRS) scores (mean) for...
-
Sep 12, 2023 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Eric Simpson
You've successfully added Dermatology: Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: 46.1% and 51% of patients achieved vIGA-AD 0 or 1 plus a 2-point improvement from baseline at weeks 28 and 56. Roflumilast was well tolerated with no new safety signals were observed.
-
Jul 19, 2023 | 
jamanetwork.com | Eric Simpson |Melinda Gooderham |Andreas Wollenberg |Stephan Weidinger
Errors in Figure 2 and Table 2 Footnotes Lebrikizumab With Corticosteroids for Moderate-to-Severe Atopic Dermatitis Eric L. Simpson, MD; Melinda Gooderham, MD; Andreas Wollenberg, MD; Stephan Weidinger, MD, PhD; April Armstrong, MD, MPH; Jennifer Soung, MD; Silvia Ferrucci, MD; Renata Gontijo Lima, MD; Michael M. Witte, PhD; Wen Xu, PhD; Hany ElMaraghy, MD; Chitra R.
-
Mar 19, 2023 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Eric Simpson
Source/Disclosures Source: Simpson E. Dupilumab treatment in patients with hand and foot atopic dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans.
